Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial,The Lancet Haematology

当前位置： X-MOL 学术 › Lancet Haematol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Isatuximab plus carfilzomib–dexamethasone versus carfilzomib–dexamethasone in patients with relapsed multiple myeloma (IKEMA): overall survival analysis of a phase 3, randomised, controlled trial
The Lancet Haematology ( IF 15.4 ) Pub Date : 2024-07-24 , DOI: 10.1016/s2352-3026(24)00148-0
Kwee Yong ₁ , Thomas Martin ₂ , Meletios-Athanasios Dimopoulos ₃ , Joseph Mikhael ₄ , Marcelo Capra ₅ , Thierry Facon ₆ , Roman Hajek ₇ , Ivan Špička ₈ , Ross Baker ₉ , Kihyun Kim ₁₀ , Gracia Martinez ₁₁ , Chang-Ki Min ₁₂ , Ludek Pour ₁₃ , Xavier Leleu ₁₄ , Albert Oriol ₁₅ , Youngil Koh ₁₆ , Kenshi Suzuki ₁₇ , France Casca ₁₈ , Sandrine Macé ₁₉ , Marie-Laure Risse ₂₀ , Philippe Moreau ₂₁

Affiliation

Department of Haematology, Cancer Institute, University College London, London, UK.
Department of Hematology, University of California at San Francisco, San Francisco, CA, USA.
The National and Kapodistrian University of Athens, Athens, Greece.
Translational Genomics Research Institute, City of Hope Cancer Center, Phoenix, AZ, USA.
Centro Integrado de Hematologia e Oncologia, Hospital Mãe de Deus, Porto Alegre, Brazil.
Department of Haematology, Lille University Hospital, Lille, France.
Department of Hemato-Oncology, University Hospital Ostrava and Faculty of Medicine, University of Ostrava, Ostrava, Czech Republic.
Department of Hematology, 1 Faculty of Medicine, Charles University and General Hospital, Prague, Czech Republic.
Perth Blood Institute, Murdoch University, Perth, Australia.
Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea.
Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
Department of Hematology, Seoul St Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, Brno, Czech Republic.
Service d'Hématologie et Thérapie Cellulaire, CHU and CIC Inserm 1402, Poitiers, France.
Institut Josep Carreras and Institut Catala d'Oncologia, Hospital Germans Trias I Pujol, Badalona, Spain.
Department of Internal Medicine, Seoul National University Hospital, Seoul, South Korea.
Myeloma/Amyloidosis Center, Japanese Red Cross Medical Center, Tokyo, Japan.
Ividata Life Science, Levallois-Perret, France.
Research and Development, Sanofi, Chilly-Mazarin, France.
Research and Development, Sanofi, Vitry-sur-Seine, France.
Department of Hematology, University Hospital Hôtel-Dieu, Nantes, France.

Isatuximab is an anti-CD38 monoclonal antibody approved for the treatment of relapsed or refractory multiple myeloma. Previous analyses of the IKEMA trial showed prolonged progression-free survival in patients with this disease who received isatuximab in combination with carfilzomib–dexamethasone as compared with those who received carfilzomib–dexamethasone alone. Herein, we report the analysis of overall survival from the IKEMA trial.

中文翻译：

Isatuximab 联合卡非佐米-地塞米松与卡非佐米-地塞米松治疗复发性多发性骨髓瘤（IKEMA）患者：3 期随机对照试验的总生存期分析

Isatuximab 是一种抗 CD38 单克隆抗体，已获批用于治疗复发或难治性多发性骨髓瘤。先前对 IKEMA 试验的分析表明，与单独接受卡非佐米-地塞米松的患者相比，接受 isatuximab 联合卡非佐米-地塞米松治疗的该疾病患者的无进展生存期延长。在此，我们报告了 IKEMA 试验的总生存期分析。

更新日期：2024-07-24

点击分享查看原文

点击收藏

阅读更多本刊新发论文